Welcome to our dedicated page for Adial Pharmaceuticals SEC filings (Ticker: ADIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Adial is a clinical-stage biopharmaceutical company focused on therapies for addictions and related disorders, and its filings document both the scientific and financial aspects of this development-stage business.
Investors can review Current Reports on Form 8-K that describe material events such as End of Phase 2 (EOP2) meeting outcomes with the U.S. Food and Drug Administration (FDA), Nasdaq listing compliance notices, equity offerings, at-the-market sales agreements, warrant amendments, and stockholder approvals for changes to the Certificate of Incorporation and equity incentive plans. These filings provide detail on the regulatory feedback shaping the AD04 Phase 3 adaptive trial design, including biomarker-positive and biomarker-negative cohorts, primary efficacy endpoints based on heavy drinking days, and statistical planning.
Filings also outline capital structure and financing arrangements, including best efforts public offerings of common stock and warrants, pre-funded warrants, and at-the-market programs. Disclosures explain how proceeds are intended for working capital and general corporate purposes and describe conditions such as exercise prices, expiration dates, and stockholder approval requirements for warrant exercises.
Through Stock Titan, users can track Nasdaq listing and compliance disclosures, including letters regarding stockholders’ equity thresholds, minimum bid price requirements, and extensions granted to regain compliance. These documents help clarify the ongoing eligibility of ADIL shares for trading on the Nasdaq Capital Market.
In addition to raw documents, Stock Titan offers AI-powered summaries that highlight key points from Adial’s 8-Ks and other filings, helping readers quickly understand complex topics such as clinical trial design guidance, intellectual property steps around AD04, and changes to authorized share counts or incentive plans. This page is a resource for anyone analyzing how Adial’s regulatory, clinical, and financing activities are reflected in its official SEC record.
Adial Pharmaceuticals announced that it has regained full compliance with Nasdaq’s minimum bid price requirement. Nasdaq confirmed that for 10 consecutive business days, from February 6 through February 20, 2026, Adial’s common stock closed at
The company highlights this as an important milestone as it advances its lead drug candidate AD04 toward a pivotal Phase 3 program for Alcohol Use Disorder and continues advanced strategic partnering discussions to support further development and potential commercialization.
ADIAL PHARMACEUTICALS ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,799,643 shares, representing 9.99% of common stock as of 12/31/2025. Armistice is the investment manager of Armistice Capital Master Fund Ltd., the direct holder; the Master Fund is listed as having the right to receive dividends or sale proceeds. The filing states voting and dispositive power over the shares is held jointly (shared power: 2,799,643), and the share counts are based on information from the issuer.
Adial Pharmaceuticals, Inc. is implementing a 1-for-25 reverse stock split of its common stock, reducing outstanding shares from approximately 27.8 million to approximately 1.1 million. The amendment to the Certificate of Incorporation becomes legally effective at 11:59 p.m. Eastern Time on February 5, 2026.
The common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on February 6, 2026, continuing under the symbol “ADIL”, with a new CUSIP of 00688A304. Fractional shares will not be issued; instead, stockholders will receive a cash payment based on the average closing price over the ten trading days before the effective time.
The company states that the primary purpose of the reverse split is to raise the per-share trading price to support continued listing on the Nasdaq Capital Market, which requires a minimum bid price of at least $1.00 per share, while noting there is no assurance the split will achieve this for the required period.
Adial Pharmaceuticals, Inc. reported that on January 5, 2025, board member James W. Newman, Jr. resigned from the company’s Board of Directors, effective immediately. He had been serving as a non-employee director and was also a member of both the Audit Committee and the Compensation Committee.
The company states that Mr. Newman did not report any disagreement with Adial on matters related to its operations, policies, or practices in connection with his resignation. The report is signed on behalf of Adial Pharmaceuticals by President and Chief Executive Officer Cary J. Claiborne.
Adial Pharmaceuticals is asking stockholders to approve the issuance of up to 13,823,512 shares of common stock upon the exercise of its Series F warrants. These warrants were granted to an institutional investor in a November 2025 warrant inducement deal, where the investor exercised earlier Series C-1 and Series E warrants for 9,215,675 shares at $0.31 per share, providing about $2.86 million in gross proceeds. If stockholders approve the warrant exercise proposal and all Series F warrants are exercised for cash at $0.31, Adial could receive up to approximately $4.3 million in additional gross proceeds. The company notes that this could significantly dilute existing holders if all shares are issued and may weigh on the stock price when sold into the market. A second proposal would allow the Board to adjourn the special meeting to solicit more votes if needed.
Adial Pharmaceuticals is registering up to 13,823,512 shares of common stock for resale by a single selling stockholder, all issuable upon exercise of Series F common stock purchase warrants. Adial is not selling shares in this prospectus and will not receive proceeds from resales, but would receive cash only if the Series F warrants are exercised.
The Series F warrants, issued in a November 2025 warrant inducement deal, have a $0.31 exercise price and a 24‑month term beginning after required stockholder approval. Adial received about $2.86 million in gross proceeds from the selling holder’s cash exercise of prior Series C‑1 and Series E warrants and estimates it could receive about $4.29 million of net proceeds if all Series F warrants are exercised, which would raise pro forma net tangible book value to roughly $0.24 per share as of September 30, 2025.
The company notes that the registered amount is large relative to its equity base, with 26,649,587 shares outstanding immediately before the offering and 40,473,099 shares if all Series F warrant shares are issued, creating potential dilution and stock overhang. Adial remains a clinical‑stage biopharmaceutical company developing AD04 for alcohol use disorder, focusing on genetically defined subgroups following its Phase 3 ONWARD trial.
Adial Pharmaceuticals, Inc. filed a current report to note that it issued a press release containing financial information for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to the report.
The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the federal securities laws and will not be incorporated by reference into other SEC filings. The report is signed on behalf of the company by President and Chief Executive Officer Cary J. Claiborne.
Adial Pharmaceuticals (ADIL) filed its Q3 2025 report, showing a net loss of $1.79 million for the quarter and $5.98 million for the nine months. Operating expenses fell as R&D declined to $521k (down ~50% year over year) while G&A was $1.24 million. Interest income was modest and losses from its Adovate equity method investment continued.
Cash and equivalents were $4.61 million at September 30, 2025. Year-to-date financing included roughly $2.2 million from a May warrant inducement and $3.0 million net from a June offering; the company also raised about $478k via its ATM in Q3. Management states cash is expected to fund operations into the second quarter of 2026, and the filing notes substantial doubt about continuing as a going concern absent additional capital.
Operationally, Adial received final FDA End of Phase 2 meeting minutes in September guiding the Phase 3 adaptive trial design for AD04 in alcohol use disorder. Common shares outstanding were 23,836,383 as of September 30, 2025; 23,987,587 as of November 7, 2025.
Adial Pharmaceuticals reported FDA feedback supporting its adaptive trial design for AD04 in alcohol use disorder (AUD). The FDA recognized AUD as an unmet need and agreed with core protocol elements including biomarker-defined positive and negative cohorts, inclusion criteria targeting moderate-to-severe AUD, trial duration, interim analysis sample size, and safety monitoring. The agency confirmed the primary efficacy endpoint of zero heavy drinking days during months 5 and 6 of the efficacy observation period and advised pre-specifying key secondary endpoints for labeling consideration. FDA also reviewed the planned interim analyses, the Statistical Analysis Plan, and the Data Monitoring Committee structure, stressing alignment among protocol, simulation report, and SAP to ensure proper alpha control and reduce post-trial analysis risk.